```html

Keratoconjunctivitis Sicca (SS‑Related Dry Eye)

Overview

Keratoconjunctivitis sicca (KCS), commonly called **dry eye**, is a chronic disorder in which the eyes do not produce enough tears—or the tears evaporate too quickly—to keep the ocular surface moist and healthy. When KCS occurs as a manifestation of **Sjögren’s syndrome (SS)**, it is referred to as “SS‑related dry eye.” Sjögren’s syndrome is an autoimmune disease that primarily attacks the body’s moisture‑producing glands, including the lacrimal (tear) glands.

Who it affects

• Adults, most often between ages 40‑60.
• Women are affected 9‑10 times more frequently than men.
• Approximately 0.1‑0.4% of the general population has primary SS; up to 70% of these patients develop dry eye.

Prevalence (global estimates, 2023)

• Dry eye disease overall: 5‑30% of adults, rising to >40% in older populations.
• In patients with confirmed SS, 65‑95% report symptomatic dry eye.

Understanding SS‑related KCS is crucial because ocular surface damage can progress quickly without proper treatment, and the condition often signals systemic autoimmune activity that requires broader medical management.

Symptoms

Symptoms may be intermittent early on and become constant as disease progresses. They can affect one or both eyes.

• Dryness or gritty sensation – feeling like sand in the eye.
• Burning, stinging, or itching – especially after reading, screen use, or exposure to wind.
• Redness – mild to moderate conjunctival injection.
• Fluctuating visual acuity – blurred vision that improves with blinking.
• Photophobia – increased sensitivity to light.
• Excessive tearing (reflex tearing) – a paradoxical response as the eye attempts to compensate.
• Foreign‑body sensation – feeling that something is stuck in the eye.
• Eye fatigue – difficulty keeping eyes open for prolonged tasks.
• Stringy mucus or crusting** – especially upon waking.
• Difficulty wearing contact lenses – intolerance or frequent dislodgement.

Causes and Risk Factors

Underlying Pathophysiology

In SS‑related KCS, auto‑antibodies (anti‑Ro/SSA, anti‑La/SSB) target the lacrimal glands, leading to lymphocytic infiltration, glandular destruction, and reduced aqueous tear production. Concurrently, inflammation of the ocular surface alters the lipid layer produced by Meibomian glands, increasing tear evaporation.

Primary Risk Factors

• Sjögren’s syndrome – primary (alone) or secondary (with rheumatoid arthritis, systemic lupus erythematosus, etc.).
• Female sex – estrogen influences tear film stability.
• Age – tear production declines with age.
• Medications – antihistamines, antidepressants, β‑blockers, isotretinoin, and diuretics reduce tear secretion.
• Environmental factors – low humidity, wind, air‑conditioned or heated rooms.
• Screen time – reduced blink rate during prolonged computer or smartphone use.
• Other autoimmune diseases – rheumatoid arthritis, systemic sclerosis, thyroid disease.

Diagnosis

Diagnosis combines patient history, clinical examination, and specific tests to confirm tear deficiency and ocular surface damage.

Step‑by‑step evaluation

1. Medical history – focus on SS diagnosis, systemic autoimmune diseases, medication list, and symptom chronology.
2. Symptom questionnaires – Ocular Surface Disease Index (OSDI) or the Sjögren’s International Collaborative Clinical Alliance (SICCA) dry eye questionnaire.
3. Slit‑lamp examination – assess conjunctival redness, corneal staining, and lid margin.
4. Tear‑film tests:
   • Schirmer I test (with anesthesia): strips placed in the lower conjunctival sac for 5 minutes; ≤5 mm wetting suggests severe aqueous deficiency.
   • Schirmer I without anesthesia can gauge reflex tearing.
   • Tear Break‑Up Time (TBUT): fluorescein dye; time <10 seconds indicates instability.
   • Osmolarity measurement (e.g., TearLab): >308 mOsm/L is abnormal.
5. Ocular surface staining – fluorescein, lissamine green, or sodium fluorescein to grade corneal and conjunctival damage (Oxford or NEI grading scales).
6. Meibomian gland evaluation – expressibility and quality of secretions; may involve meibography.
7. Laboratory work‑up (if SS not yet diagnosed) – ANA, rheumatoid factor, anti‑Ro/SSA, anti‑La/SSB, ESR, CRP.

Diagnosis is confirmed when clinical signs (e.g., Schirmer ≤5 mm, TBUT <10 s, positive staining) align with a known SS diagnosis or serologic evidence of the disease.

Treatment Options

Treatment aims to restore tear film stability, control inflammation, and protect the ocular surface. Therapy is often layered—starting with artificial tears and escalating to prescription medications or procedures.

1. Artificial Tears & Lubricants

• Preservative‑free drops – recommended for >4 times daily use; options include carboxymethylcellulose (Refresh Optive) or hyaluronic acid (Hylo‑Comod).
• Gel or ointment** – applied at night for prolonged lubrication (e.g., Refresh PM).
• Contact lens‑compatible solutions** – for patients who wear lenses.

2. Anti‑Inflammatory Therapy

• Topical cyclosporine A 0.05% (Restasis) or 0.1% (Cequa) – improves tear production by inhibiting T‑cell activation; takes 4‑6 weeks for effect.
• Topical lifitegrast 5% (Xiidra) – blocks LFA‑1/ICAM‑1 interaction; reduces inflammation and discomfort.
• Short‑course corticosteroid eye drops – for acute severe inflammation; must be tapered under physician supervision.

3. Punctal Occlusion

Insertion of tiny silicone plugs into the nasolacrimal puncta reduces tear drainage, increasing tear residence time. Options: temporary (collagen) or permanent (silicone) plugs.

4. Meibomian Gland Therapy

• Lid hygiene – warm compresses 5‑10 minutes followed by gentle massage.
• In‑office thermal pulsation (e.g., LipiFlow) – restores gland function.
• Topical azithromycin or oral doxycycline – anti‑inflammatory effect on meibomian glands.

5. Autologous Serum Eye Drops

Serum derived from the patient’s own blood contains growth factors and vitamins that promote epithelial healing. Typically 20‑50% dilution, used 4‑6 times daily for severe refractory cases.

6. Scleral or Bandage Contact Lenses

Large‑diameter lenses (e.g., PROSE, BostonSight) create a fluid reservoir over the cornea, protecting it and providing continuous lubrication.

7. Systemic Therapy (for underlying SS)

• Hydroxychloroquine – disease‑modifying antirheumatic drug (DMARD) that can reduce systemic autoimmune activity.
• Biologics (e.g., rituximab) – considered in refractory systemic SS; may indirectly improve ocular symptoms.

8. Lifestyle & Environmental Modifications

• Humidifier use (≥40% relative humidity).
• Protective eyewear outdoors.
• Limit caffeine/alcohol, which can dehydrate the body.
• Scheduled blinking during screen time (20‑20‑20 rule).

Living with Keratoconjunctivitis sicca (SS‑related dry eye)

Effective self‑care reduces flare‑ups and improves quality of life.

• Establish a drop schedule – keep a log to ensure regular artificial‑tear use.
• Warm compress routine – 5 minutes twice daily, followed by gentle lid massage.
• Hydration – aim for 2‑3 L of water per day.
• Nutrition – omega‑3 fatty acids (fish oil, flaxseed) have modest benefit; 1000 mg EPA/DHA daily is commonly recommended.
• Screen ergonomics – keep screen at eye level, maintain a 20‑inch distance, and use blinking reminders.
• Protect eyes from wind and smoke – wear wrap‑around sunglasses or goggles.
• Regular follow‑up – every 3‑6 months with an ophthalmologist familiar with dry eye and SS.
• Document systemic symptoms – fatigue, joint pain, or gland swelling should be reported to the rheumatologist.

Prevention

While SS itself cannot be prevented, the severity of dry‑eye manifestations can be mitigated.

• Early diagnosis of SS and prompt systemic treatment.
• Avoid or minimize use of systemic drugs known to reduce tear production when alternatives exist.
• Maintain a moist indoor environment (humidifiers) during winter heating or in air‑conditioned offices.
• Adopt protective eyewear for windy, dusty, or smoky conditions.
• Implement regular eye‑care habits (lid hygiene, artificial tears) before symptoms become severe.

Complications

If left untreated, SS‑related KCS can lead to serious ocular pathology.

• Corneal epitheliopathy – persistent staining, erosions, and ulceration.
• Superficial punctate keratitis – fine, dot‑like epithelial defects that cause pain.
• Infectious keratitis – bacterial, fungal, or viral infection due to compromised surface.
• Scarring and neovascularization – may impair vision.
• Sentinel ulcer or perforation – rare but sight‑threatening emergencies.
• Reduced contact‑lens tolerance – leading to discontinuation of lens wear.
• Impact on quality of life – chronic discomfort, reduced productivity, and psychological stress.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Dry eye disease.” 2023; CDC. “Sjogren’s syndrome.” 2022; NIH National Eye Institute. “Keratoconjunctivitis sicca.” 2024; WHO. “Autoimmune diseases data.” 2023; Cleveland Clinic. “Dry eye treatment options.” 2024; Ophthalmology journal, 2022; Arthritis & Rheumatology, 2021.

```